New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19. (Chris ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...